High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study
This article was originally published in The Tan Sheet
Executive Summary
Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found